Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August 11, 2007, issue of The Lancet. The study suggests that treatment with Kuvan results in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. Kuvan, an investigational oral small molecule for the treatment of PKU, is being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"This marks the first published Kuvan clinical study, and we expect additional publications in the coming months to build on the collection of data related to Kuvan," said Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin. "We recently received priority review from the FDA and hope to receive FDA approval by late November. In the interim, we are pleased to be able to provide Kuvan to PKU patients prior to commercial availability through our expanded access program."

The Phase 3 clinical study enrolled 89 patients with elevated blood Phe levels aged eight years and above at 29 sites in the United States, Europe and Canada. All patients enrolled had demonstrated a reduction in blood Phe levels following treatment with Kuvan in a Phase 2 screening study.

The patients were randomly assigned to receive placebo or 10 mg/kg of Kuvan daily for six weeks. Patients were evaluated every two weeks for changes in blood Phe levels and adverse events. The primary objective was to assess the efficacy of Kuvan compared with placebo for reduction of blood phenylalanine in patients with PKU. The secondary objective was to assess the safety of Kuvan compared with placebo. A total of 87 patients completed six weeks of treatment.

Highlights from the Phase 3 double-blind study are summarized below:

* Patients treated with Kuvan for six weeks had a mean decrease
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
(Date:3/4/2015)... , March 4, 2015  Students from Indiana University ... how new medicines are discovered. Through a partnership with ... medical students from IU School of Medicine are learning ... at Lilly play different and important roles in bringing ... a former medical educator, scientific investigator, and health system ...
(Date:3/4/2015)... 4, 2015   InspireMD, Inc.  ("InspireMD" or the ... systems ("EPS"), today announced that it has entered into ... million shares of common stock and warrants to purchase ... in a public offering.  The common stock will be ... share, and each purchaser will receive a warrant to ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 2Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 3InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4
(Date:3/4/2015)... Ultraman Florida is a grueling extreme athletic ... bike, and 52.4 mile run. Christian Isakson finished in ... "This race was awesome and tough," Isakson said. "I ... for supporting me through every part of this brutal ... of 40 select participants invited from across the United ...
(Date:3/4/2015)... March 04, 2015 TROY Healthcare Solutions ... which provides the ultimate level of security for prescriptions, ... Hilton Houston Plaza Medical Center located at 6633 Travis ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief presentations each hour to introduce ...
(Date:3/4/2015)... Smokers across America are the target ... Love Smokers' from Aqua-Tine, the new brand that helps ... important to establish a clear point of view for ... 'We Love Smokers' elevates the Aqua-Tine brand, gives it ... a bold tone of voice that is also genuinely ...
(Date:3/4/2015)... 04, 2015 Starting February 2015, Dr. ... PRK procedures at their new location in Surrey. , ... King and Dr. Gabriel Chu also provide comprehensive ophthalmology ... is named Fraser Valley Cataract and Laser (FVCL). This ... the College of Physicians and Surgeons of British Columbia. ...
(Date:3/4/2015)... " Optrix by Body Glove ” was ... Report, which takes a look at the latest and ... Steinberg, a special reporter for NewsWatch and a technology ... how they have an ultra-rugged, waterproof case with an ... major player at the Consumer Electronics Show in Las ...
Breaking Medicine News(10 mins):Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:King LASIK relocates to Surrey, British Columbia 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2
... Minn. -- The Medical Publishing Insights and Practices ... journal editors to characterize the persistent and perceived ... identify potential approaches to resolve it. This unique ... Ten Recommendations for Closing the Credibility Gap in ...
... By Randy Dotinga HealthDay Reporter , MONDAY, May ... front of the TV have poorer diets overall, a new study ... that TV watching has anything to do with what kids eat, ... more important than time spent with "American Idol" or "SpongeBob SquarePants." ...
... -- Giving earplugs to patients in the intensive care unit ... onset of delirium, according to a new study. It ... delirium in ICU patients, and research has shown that ICU ... in the ICU from equipment and people coming and going. ...
... hard to diagnose as well as treat, but researchers at ... discovered a way of confirming the disorder using stool samples. ... with pain and discomfort in the abdomen together with changes ... to be linked to dysfunction of the stomach and intestines, ...
... risk of prostate cancer can be beneficial in reducing ... states an article published in CMAJ ( ... Preventive Services Task Force, which last issued prostate screening ... prostate-specific antigen (PSA) screening for men of all ages. ...
... Professor Keon Jae Lee ( http://fand.kaist.ac.kr/ ) from ... has developed new forms of low cost, large-area ... Piezoelectric effects-based nanogenerator technology that converts existing sources ... energy from the nature of wind and waves, ...
Cached Medicine News:Health News:Journals and pharma collaborate on new recommendations 2Health News:Lots of TV May Harm Kids' Diet 2Health News:Lots of TV May Harm Kids' Diet 3Health News:Using Earplugs Eases ICU Patients' Confusion: Study 2Health News:PSA screening to detect prostate cancer can be beneficial to younger and at-risk men 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 11 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Medicine Products: